Communiqué from LinkMed's extraordinary meeting of shareholders

Communiqué from LinkMed's extraordinary meeting of shareholders

LinkMed AB (publ) held an extraordinary meeting of shareholders on July 22, 2008
at 10:00am in Stockholm. 

Shareholders at the meeting voted, as a part of the acquisition of Olerup SSP
AB, in approval of the issuance of LinkMed AB convertibles, by means of which
the company will borrow a maximum of SEK 31 million. Interest is set at 6% and
is paid quarterly. The right to subscribe is reserved solely for SSP Primers AB.
Payment will be made through contribution in kind in the form of shares in
Olerup SSP AB.   Conversion may be requested from the date of registration at
the Swedish Companies Registration Office until and including June 30, 2013. The
conversion rate shall be 150% of the average share price of the LinkMed share
for the period June 9 to July 18, 2008, which was SEK 29.34.





For more information contact:
Ingemar Lagerlöf, CEO		+46 8 508 939 93
Okee Williams, Portfolio Manager 	+46 8 508 939 40


LinkMed, in collaboration with innovators, develops new life science companies.
By contributing entrepreneurship and capital, LinkMed has created a portfolio of
eleven companies, six in biotechnology and five in medical technology. The
company's principal owners are FastPartner, Koncentra Holding, and the founder
Ingemar Lagerlöf. The LinkMed share is listed on the OMX Nordic Exchange
Stockholm in the small-cap sector (ticker:LMED). See www.linkmed.se for more
information.